SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SUNPHARM Pharmaceuticals (SUNP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Metacomet who wrote (25)2/1/1999 6:56:00 PM
From: JMarcus  Read Replies (1) of 52
 
I am not aware of any fundamental reasons for the stock's sell-off during the latter part of 1998. Shares are very very thinly traded, and there is precious little news coverage. I attribute the last fall's downward direction in the stock price to investor impatience and the extent of the fall to the very low volume of sales. Today's volume was more than 50% higher than the highest volume on any day last year. When this stock was in the $4-6 range, I thought it was cheap, and I still think it would be cheap at that price. If we get good news on Warner-Lambert's DENSPM trial in the first half of this year, as expected, the effect on stock price would be explosive.

On the other thread Braveheart asked (inter alia) about the toxicity and side effect issues with DENSPM. At his Informed Investor Forum presentation, CEO Stefan Berg said that the side effects were nausea and vomiting, which were dose-related. He believes that they are readily controllable by managing dosage of the drug, and opined that those side effects could also be managed with other drugs. For a cancer drug, these are very tolerable side effects.

Starting out DENSPM's Phase 2 testing in six separate tumor types reflects SUNP's strategy of taking advantage of off-label usage in multiple tumor types after first getting fast FDA approval in the tumor type where efficacy is most easily proven. DENSPM is being tested as a monotherapy for cancer, which will create the biggest marketing impact if the trials are successful.

Marc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News